Preclinical Evaluation of a Novel 99mTc-Labeled CB86 for Rheumatoid Arthritis Imaging

Peng Liu; Tingting Wang; Rongshui Yang; Wentao Dong; Qiang Wang; Zhide Guo; Chao Ma; Weixing Wang; Huaibo Li; Xinhui Su

doi:10.1021/acsomega.0c04066

Preclinical Evaluation of a Novel ^99mTc-Labeled CB86 for Rheumatoid Arthritis Imaging

ACS Omega. 2020 Nov 30;5(49):31657-31664. doi: 10.1021/acsomega.0c04066. eCollection 2020 Dec 15.

Authors

Peng Liu¹, Tingting Wang¹, Rongshui Yang¹, Wentao Dong¹, Qiang Wang¹, Zhide Guo², Chao Ma¹, Weixing Wang¹, Huaibo Li³, Xinhui Su¹

Affiliations

¹ Department of Nuclear Medicine, Zhongshan Hospital Xiamen University, Xiamen 361004, China.
² Center for Molecular Imaging and Translational Medicine, Xiamen University, Xiamen 361102, China.
³ Department of Health Medicine, Zhongshan Hospital Xiamen University, Xiamen 361004, China.

Abstract

Early diagnosis and therapy are crucial to control disease progression optimally and achieve a good prognosis in rheumatoid arthritis (RA). Previous study showed that a technetium-99m (^99mTc)-labeled TSPO ligand (^99mTc-CB256 [2-(8-(2-(bis(pyridin-2-yl)methyl)amino)acetamido)-2-(4-chlorophenyl)H-imidazo[1,2-a]pyridin-3-yl)-N,N-dipropylacetamide] composed of a translocator protein (TSPO) ligand CB86 [[2-(4-chlorophenyl)-8-amino-imidazo[1,2-a]-pyridin-3-yl]-N,N-di-n-propylacetamide] and di-(2-picolyl)amine, a bifunctional chelate agent, was used to image a TSPO-rich cancer cell in vitro; however, few ^99mTc-CB256 in vivo evaluation has been reported so far probably due to the cytotoxicity of CB256 (ca. 75 times more than analogous CB86). Herein, we describe a novel TSPO targeting radiopharmaceutical consisting of CB86 and diethylenetriaminepentaacetic acid (DTPA), a conventional bifunctional chelating ligand in clinical trials used to prepare ^99mTc-labeled CB86, and its evaluation as a ^99mTc-single-photon emission computed tomography (SPECT) probe. The radiosynthesis and characterization of ^99mTc-DPTA-CB86 including hydrophilicity and stability tests were determined. Additionally, the binding affinity and specificity of ^99mTc-DTPA-CB86 to TSPO were evaluated using RAW264.7 macrophage cells. Biodistribution and ^99mTc-SPECT studies were conducted on rheumatoid arthritis (RA) rat models after the injection of ^99mTc-DTPA-CB86 with or without co-injection of unlabeled DTPA-CB86. The radiosynthesis of ^99mTc-DTPA-CB86 was completed successfully with the labeling yields and radiochemical purity of 95.86 ± 2.45 and 97.45 ± 0.69%, respectively. The probe displayed good stability in vitro and binding specificity to RAW264.7 macrophage cells. In the biodistribution studies, ^99mTc-DTPA-CB86 exhibited rapid inflammatory ankle accumulation. At 180 min after administration, ^99mTc-DTPA-CB86 uptakes of the left inflammatory ankle were 2.35 ± 0.10 percentage of the injected radioactivity per gram of tissue (% ID/g), significantly higher than those of the normal tissues. ^99mTc-SPECT imaging studies revealed that ^99mTc-DTPA-CB86 could clearly identify the left inflammatory ankle with good contrast at 30-180 min after injection. Therefore, ^99mTc-DTPA-CB86 may be a promising probe for arthritis ^99mTc-SPECT imaging.